Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival

Glioblastoma (GBM) is the most malignant brain tumor where patients' survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet need for novel, effective therapeutic strategies for this devastating disease...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Poli, Aurélie, Wang, Jian, Domingues, Olivia, Planagumà, Jesús, Yan, Tao, Rygh, Cecilie Brekke, Skaftnesmo, Kai Ove, Thorsen, Frits, McCormack, Emmet, Hentges, François, Pedersen, Paal Henning, Zimmer, Jacques, Enger, Per Øyvind, Chekenya, Martha
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2013
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3824525/
https://ncbi.nlm.nih.gov/pubmed/24127551
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados